Technology
100 Most Popular
Most Popular Under $25

Viking Therapeutics

$8.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.02 (-10.99%) Today
+$0.10 (1.21%) After Hours

Why Robinhood?

You can buy or sell VKTX and other stocks, options, ETFs, and crypto commission-free!

About

Viking Therapeutics, Inc. Common Stock, also called Viking Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. Read More The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Employees
15
Headquarters
San Diego, California
Founded
2012
Market Cap
592.59M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
3.29M
High Today
$9.26
Low Today
$8.25
Open Price
$9.16
Volume
2.02M
52 Week High
$24.00
52 Week Low
$3.69

Collections

Technology
100 Most Popular
Most Popular Under $25
Health
Biotechnology
Top Movers
Medical
Therapy

News

The Motley FoolMar 14

Viking Therapeutics (VKTX) Q4 2018 Earnings Conference Call Transcript

Viking Therapeutics (NASDAQ:VKTX) Q4 2018 Earnings Conference Call March 13, 2019 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Viking Therapeutics fourth-quarter 2018 and year-end earnings conference call. [Operator instructions] Please note, this event is being recorded. I would now like to turn the conference over to Stephanie Diaz, investor relations. Please go ahead. Stephanie Diaz -- Investor Rela...

3,771
MarketBeatMar 5

Stock Price, News, & Analysis for Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content,...

2,265
Guru FocusFeb 26

Viking Therapeutics to Participate in Upcoming Investor Conferences and Events

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences and events. Details of these presentations are as follows: Raymond James 40 th Annual Institutional Investors Conference Time/Date: 8:05 a.m. ET on Monday , March 4, 2019 (webcast available) Locatio...

3,411

Earnings

-$0.22
-$0.17
-$0.12
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.10 per share
Actual
-$0.07 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.